.jpg)
.png)
NLA News
The National Lipid Association has endorsed the following Guidelines: Management of Overweight and Obese Adults Lifestyle Management to Reduce Cardiovascular Risk Assessment of Cardiovascular Risk The ACC and the American Heart Association (AHA), in collaboration with... more
The National Lipid Association (NLA) is excited to announce it has submitted a proposal to the National Center for Health Statistics (NCHS) to create new, specific ICD-10 codes for FH, which would include homozygous FH and heterozygous FH. The NCHS is the Federal agency responsible for revising the... more
The National Committee for Quality Assurance (NCQA) has proposed retiring the use of LDL-C treatment targets in response to the new ACC/AHA Task Force on Practice Guidelines. The NCQA has stated that no studies focus on treatment or titration to a specific LDL-C goal in adults with clinical... more
Special Education Session at the Orlando 2014 Annual Scientific Sessions: The National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia Friday, May 2 • 6:45 – 7:45 a.m. As you know, the American College of Cardiology and the American Heart... more
After years of thoughtful planning and development, the National Lipid Association (NLA) recently released its first edition of the Annual Summary of Clinical Lipidology. The first issue, which was published as a supplement to the November/December issue of the Journal of Clinical... more
The National Lipid Association (NLA) endorses the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk, published by the American College of Cardiology on April 1 in the Journal... more
The results of the HPS2-THRIVE study were released in the New England Journal of Medicine on July 17, 2014. Also, appearing in the same edition was a special correspondence from the AIM HIGH investigators concerning further analysis of adverse events, and an editorial addressing both of... more
Amgen announced today that the FOURIER trial met its primary and secondary endpoints in evaluating whether evolocumab reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) without new safety issues. Amgen also announced that the... more
The American Board of Clinical Lipidology (ABCL) Board of Directors has published a list of recommended reading for those preparing for maintenance of certification (MOC). If you’re studying for the exam, you can find a list of suggested reading at lipidboard.org/moc. The ABCL’s MOC... more
On Sunday, Nov. 16, at the American Heart Association (AHA) Scientific Sessions, W. Virgil Brown, MD—Editor-in-Chief of the Journal of Clinical Lipidology and Founding President of the National Lipid Association (NLA)—facilitated and participated in a debate about cholesterol targets. The session (... more